TY - JOUR
T1 - Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review
AU - de Vroom, Suzanne L.
AU - van Daalen, Frederike V.
AU - Zieck, Saskia E.
AU - Mathôt, Ron A. A.
AU - van Hest, Reinier M.
AU - Geerlings, Suzanne E.
N1 - Funding Information: RAAM reports grants from Baxter/Baxalta/Shire, grants from Bayer Schering Pharma, grants from CSL Behring, grants from Merck Sharp & Dohme and grants from Zeria, outside the submitted work. RMvH reports grants from Nordic Pharma, outside the submitted work. SEG reports grants from Nordic Pharma and grants from Vifor Pharma, outside the submitted work. The other authors report no conflicts of interest relevant to this review. Publisher Copyright: © 2020 The Authors
PY - 2021/3
Y1 - 2021/3
N2 - Background: There is inconsistency between many guidelines in the recommended dose reduction of renally cleared antibiotics in patients with impaired renal function. Objectives: This systematic review summarizes the available evidence on the adequacy of the recommended dose reduction in terms of achieving sufficient antibiotic drug exposure or pharmacokinetic/pharmacodynamic target attainment after treatment with these reduced doses. Data sources: We systematically searched Ovid Medline and Embase from inception (respectively 1946 and 1947) through July 2019. Study eligibility criteria: All studies reporting antibiotic drug exposure and/or pharmacokinetic/pharmacodynamic (PK/PD) target attainment after dose reduction of antibiotics in patients with impaired renal function. Participants: Adult patients with or without infections. Interventions: Administration of reduced doses of antibiotics (orally, intravenously or intramuscularly). Methods: The reduced dose was considered adequate when the most relevant parameters of drug exposure or PK/PD target attainment in patients with impaired renal function were within a range of 80% to 125% of that patients with adequate renal function receiving a regular dose (reference) or when PK/PD target attainment was attained in at least 90% of the patients with impaired renal function, regardless of the lack of a reference group. Results: Twenty-seven of the 4202 identified studies were included. The quality of 15 of 27 studies was fair, and most studies were of β-lactams (12/27). Best evidence was available for meropenem: four studies were included, of which two studies were of good quality. Drug exposure for meropenem is 158% to 286% higher in patients with impaired renal function receiving reduced doses compared to patients with adequate renal function receiving regular doses. For all other antibiotics, a maximum of one good-quality study could be identified. Conclusions: No good-quality evidence on the recommended dose reduction of renally cleared antibiotics in patients with impaired renal function is present, with the exception of meropenem.
AB - Background: There is inconsistency between many guidelines in the recommended dose reduction of renally cleared antibiotics in patients with impaired renal function. Objectives: This systematic review summarizes the available evidence on the adequacy of the recommended dose reduction in terms of achieving sufficient antibiotic drug exposure or pharmacokinetic/pharmacodynamic target attainment after treatment with these reduced doses. Data sources: We systematically searched Ovid Medline and Embase from inception (respectively 1946 and 1947) through July 2019. Study eligibility criteria: All studies reporting antibiotic drug exposure and/or pharmacokinetic/pharmacodynamic (PK/PD) target attainment after dose reduction of antibiotics in patients with impaired renal function. Participants: Adult patients with or without infections. Interventions: Administration of reduced doses of antibiotics (orally, intravenously or intramuscularly). Methods: The reduced dose was considered adequate when the most relevant parameters of drug exposure or PK/PD target attainment in patients with impaired renal function were within a range of 80% to 125% of that patients with adequate renal function receiving a regular dose (reference) or when PK/PD target attainment was attained in at least 90% of the patients with impaired renal function, regardless of the lack of a reference group. Results: Twenty-seven of the 4202 identified studies were included. The quality of 15 of 27 studies was fair, and most studies were of β-lactams (12/27). Best evidence was available for meropenem: four studies were included, of which two studies were of good quality. Drug exposure for meropenem is 158% to 286% higher in patients with impaired renal function receiving reduced doses compared to patients with adequate renal function receiving regular doses. For all other antibiotics, a maximum of one good-quality study could be identified. Conclusions: No good-quality evidence on the recommended dose reduction of renally cleared antibiotics in patients with impaired renal function is present, with the exception of meropenem.
KW - Dose reduction of antibiotics
KW - Drug exposure
KW - Impaired renal function
KW - Pharmacokinetic/pharmacodynamic target attainment
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85099869950&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.cmi.2020.11.032
DO - https://doi.org/10.1016/j.cmi.2020.11.032
M3 - Review article
C2 - 33290864
SN - 1469-0691
VL - 27
SP - 352
EP - 363
JO - Clinical Microbiological and Infection
JF - Clinical Microbiological and Infection
IS - 3
ER -